Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Magagnoli, Massimo
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -	Recruiting	N/A	190	Europe	acalabrutinib, Calquence	AstraZeneca, Yghea	Chronic Lymphocytic Leukemia	02/30	02/30
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)	Recruiting	N/A	59	Europe		IRCCS Azienda Ospedaliero-Universitaria di Bologna	Marginal Zone Lymphoma(MZL)	06/25	06/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Magagnoli, Massimo
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -	Recruiting	N/A	190	Europe	acalabrutinib, Calquence	AstraZeneca, Yghea	Chronic Lymphocytic Leukemia	02/30	02/30
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)	Recruiting	N/A	59	Europe		IRCCS Azienda Ospedaliero-Universitaria di Bologna	Marginal Zone Lymphoma(MZL)	06/25	06/25